Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on the Safety of Encorafenib, Binimetinib, and Ribociclib for Patients with Solid Tumors

Fast replyRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of treatments for solid tumors, which are abnormal masses of tissue that usually do not contain cysts or liquid areas. The study involves the use of two medications: Encorafenib and Binimetinib. Encorafenib is a type of medication that targets specific proteins in cancer cells, while Binimetinib works by blocking certain enzymes that promote cancer cell growth. These medications are being tested to see how safe and tolerable they are for patients who have been benefiting from them in previous studies.

The purpose of this study is to monitor the safety and tolerability of these treatments. Participants will continue to receive the study medications as long as they are benefiting from them. The study will last for a maximum of 60 months, during which participants will have regular check-ups to monitor their health and any side effects they may experience. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual medications.

Throughout the study, participants will be closely monitored for any adverse effects, which are unwanted or harmful reactions to the medications. The study aims to identify any serious adverse events (SAEs) that might lead to the permanent discontinuation of the study medications. This information will help researchers understand the long-term safety of Encorafenib and Binimetinib for treating solid tumors.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, the participant must be currently receiving treatment and benefiting from a previous encorafenib/binimetinib study. The participant should not have any severe or intolerable side effects related to the treatment.

    The participant must agree to follow specific reproductive guidelines and be willing to comply with all scheduled visits and procedures as outlined in the study protocol.

  2. Step 2

    Treatment administration

    The participant will continue receiving the study medications, which may include binimetinib, encorafenib, ribociclib, cetuximab, and vemurafenib. These medications are administered in various forms such as film-coated tablets, hard capsules, and solutions for infusion.

    The medications are primarily taken orally, except for cetuximab, which is given as a solution for infusion. The specific dosage and frequency will be determined by the study protocol and the participant's previous treatment regimen.

  3. Step 3

    Monitoring and follow-up

    The main objective of the study is to monitor the safety and tolerability of the treatment. This involves regular check-ups and assessments to ensure the participant's well-being.

    The study will track any adverse events (AEs) that may lead to the discontinuation of the treatment, as well as any serious adverse events (SAEs).

  4. Step 4

    Completion of the study

    The estimated end date for the study is December 31, 2026. The participant will continue to receive treatment and be monitored until this date or until the study is concluded for other reasons.

    Upon completion, the participant will undergo a final assessment to evaluate the overall impact of the treatment.

Who can join the trial?

8 criteria

  • Participants must have **solid tumors**. Solid tumors are abnormal masses of tissue that usually do not contain liquid areas.
  • Participants should be currently receiving the study treatment and benefiting from it, as determined by the main doctor in charge. They should not have any severe or intolerable side effects related to the treatment.
  • Participants must agree to follow specific rules about reproduction, which are detailed in the study's guidelines for both males and females.
  • Participants should be willing and able to attend all scheduled visits and follow the treatment plan and other procedures as outlined in the study's guidelines.
  • Participants must be able to give signed informed consent, which means they understand and agree to the study's requirements and restrictions.
  • The study is open to both male and female participants.
  • The study includes participants from certain age groups, specifically adults and older adults.
  • The study may include individuals who are considered part of a vulnerable population, meaning they might need extra protection or care.

Who cannot join the trial?

5 criteria

  • Patients with medical conditions other than solid tumors cannot participate. Solid tumors are a type of cancer that forms in solid organs or tissues.
  • Patients who are not within the specified age range cannot participate. The age range for this study is not specified in the provided data.
  • Patients who are not part of the specified clinical trial groups cannot participate. The specific group for this study is not detailed in the provided data.
  • Patients who are not male or female cannot participate, as the study includes both genders.
  • Patients who are considered part of a vulnerable population cannot participate. Vulnerable populations include groups that may have limited ability to give informed consent or are at higher risk of harm.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

RecruitingNot yet recruitingNot recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Encorafenib

    is a medication used in the treatment of certain types of cancer. It works by blocking the action of a protein that helps cancer cells grow. This medication is often used in combination with other treatments to help stop the spread of cancer.

  • Binimetinib

    is another medication used to treat cancer. It targets specific proteins in cancer cells, helping to slow down or stop their growth. Binimetinib is typically used alongside other medications to enhance its effectiveness in treating cancer.

What is already known about the treatment

  • Encorafenib

    Encorafenib is administered orally in the form of tablets. It is currently being studied in clinical trials for its effectiveness in treating solid tumors. The medication works by inhibiting a specific protein called BRAF, which is involved in cell growth and division, thereby slowing down or stopping the growth of cancer cells. Encorafenib is classified as a BRAF inhibitor, a type of targeted cancer therapy.

  • Binimetinib

    Binimetinib is taken orally as tablets and is under investigation in clinical trials for its use in treating solid tumors. It functions by blocking a protein known as MEK, which is part of a pathway that helps cancer cells grow and survive. By inhibiting this protein, binimetinib can help reduce tumor growth. It belongs to the class of medications known as MEK inhibitors, which are used in targeted cancer therapy.

Investigated diseases

Solid Tumors – Solid tumors are abnormal masses of tissue that usually do not contain cysts or liquid areas. They can occur in various parts of the body, including organs and bones. These tumors are characterized by the uncontrolled growth of cells that form a lump or mass. As they progress, they may grow larger and potentially spread to other parts of the body. The growth rate and behavior of solid tumors can vary widely depending on their type and location. They are distinct from blood-related cancers, which do not form solid masses.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-509408-13-00Protocol codeC4221026Estimated enrolment103 patientsSponsorPfizer Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.